Susceptibility of pancreatic cancer stem cells to reprogramming

Kozo Noguchi, Hidetoshi Eguchi, Masamitsu Konno, Koichi Kawamoto, Naohiro Nishida, Jun Koseki, Hiroshi Wada, Shigeru Marubashi, Hiroaki Nagano, Yuichiro Doki, Masaki Mori, Hideshi Ishii

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Previous reports have indicated that reprogramming technologies may be useful for altering the malignant phenotype of cancer cells. Although somatic stem cells in normal tissues are more sensitive to reprogramming induction than differentiated cells, it remains to be elucidated whether any specific subpopulations are sensitive to reprogramming in heterogeneous tumor tissues. Here we examined the susceptibility of pancreatic cancer stem cells (CSC) and non-CSC to reprogramming. To characterize CSC populations, we focused on c-Met signaling, which has been identified as a marker of CSC in mouse experiments in vivo. Cells that expressed high levels of c-Met showed higher CSC properties, such as tumor-initiating capacity, and resistance to gemcitabine. Real-time reverse transcription-polymerase chain reaction in cells expressing high levels of c-Met revealed endogenous expression of reprogramming factors, such as OCT3/4, SOX2, KLF4 and cMYC. Introduction of these four factors resulted in higher alkaline phosphatase staining in cells with high c-Met expression than in controls. Therefore, the study results demonstrate that cellular reprogramming may be useful for extensive epigenetic modification of malignant features of pancreatic CSC.

Original languageEnglish
Pages (from-to)1182-1187
Number of pages6
JournalCancer Science
Volume106
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Neoplastic Stem Cells
Pancreatic Neoplasms
gemcitabine
Neoplasms
Adult Stem Cells
Epigenomics
Reverse Transcription
Alkaline Phosphatase
Stem Cells
Cellular Reprogramming
Staining and Labeling
Technology
Phenotype
Polymerase Chain Reaction
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Noguchi, K., Eguchi, H., Konno, M., Kawamoto, K., Nishida, N., Koseki, J., ... Ishii, H. (2015). Susceptibility of pancreatic cancer stem cells to reprogramming. Cancer Science, 106(9), 1182-1187. https://doi.org/10.1111/cas.12734

Susceptibility of pancreatic cancer stem cells to reprogramming. / Noguchi, Kozo; Eguchi, Hidetoshi; Konno, Masamitsu; Kawamoto, Koichi; Nishida, Naohiro; Koseki, Jun; Wada, Hiroshi; Marubashi, Shigeru; Nagano, Hiroaki; Doki, Yuichiro; Mori, Masaki; Ishii, Hideshi.

In: Cancer Science, Vol. 106, No. 9, 01.09.2015, p. 1182-1187.

Research output: Contribution to journalArticle

Noguchi, K, Eguchi, H, Konno, M, Kawamoto, K, Nishida, N, Koseki, J, Wada, H, Marubashi, S, Nagano, H, Doki, Y, Mori, M & Ishii, H 2015, 'Susceptibility of pancreatic cancer stem cells to reprogramming', Cancer Science, vol. 106, no. 9, pp. 1182-1187. https://doi.org/10.1111/cas.12734
Noguchi K, Eguchi H, Konno M, Kawamoto K, Nishida N, Koseki J et al. Susceptibility of pancreatic cancer stem cells to reprogramming. Cancer Science. 2015 Sep 1;106(9):1182-1187. https://doi.org/10.1111/cas.12734
Noguchi, Kozo ; Eguchi, Hidetoshi ; Konno, Masamitsu ; Kawamoto, Koichi ; Nishida, Naohiro ; Koseki, Jun ; Wada, Hiroshi ; Marubashi, Shigeru ; Nagano, Hiroaki ; Doki, Yuichiro ; Mori, Masaki ; Ishii, Hideshi. / Susceptibility of pancreatic cancer stem cells to reprogramming. In: Cancer Science. 2015 ; Vol. 106, No. 9. pp. 1182-1187.
@article{aaf24228d59f456cb89f392653265059,
title = "Susceptibility of pancreatic cancer stem cells to reprogramming",
abstract = "Previous reports have indicated that reprogramming technologies may be useful for altering the malignant phenotype of cancer cells. Although somatic stem cells in normal tissues are more sensitive to reprogramming induction than differentiated cells, it remains to be elucidated whether any specific subpopulations are sensitive to reprogramming in heterogeneous tumor tissues. Here we examined the susceptibility of pancreatic cancer stem cells (CSC) and non-CSC to reprogramming. To characterize CSC populations, we focused on c-Met signaling, which has been identified as a marker of CSC in mouse experiments in vivo. Cells that expressed high levels of c-Met showed higher CSC properties, such as tumor-initiating capacity, and resistance to gemcitabine. Real-time reverse transcription-polymerase chain reaction in cells expressing high levels of c-Met revealed endogenous expression of reprogramming factors, such as OCT3/4, SOX2, KLF4 and cMYC. Introduction of these four factors resulted in higher alkaline phosphatase staining in cells with high c-Met expression than in controls. Therefore, the study results demonstrate that cellular reprogramming may be useful for extensive epigenetic modification of malignant features of pancreatic CSC.",
author = "Kozo Noguchi and Hidetoshi Eguchi and Masamitsu Konno and Koichi Kawamoto and Naohiro Nishida and Jun Koseki and Hiroshi Wada and Shigeru Marubashi and Hiroaki Nagano and Yuichiro Doki and Masaki Mori and Hideshi Ishii",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/cas.12734",
language = "English",
volume = "106",
pages = "1182--1187",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Susceptibility of pancreatic cancer stem cells to reprogramming

AU - Noguchi, Kozo

AU - Eguchi, Hidetoshi

AU - Konno, Masamitsu

AU - Kawamoto, Koichi

AU - Nishida, Naohiro

AU - Koseki, Jun

AU - Wada, Hiroshi

AU - Marubashi, Shigeru

AU - Nagano, Hiroaki

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Ishii, Hideshi

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Previous reports have indicated that reprogramming technologies may be useful for altering the malignant phenotype of cancer cells. Although somatic stem cells in normal tissues are more sensitive to reprogramming induction than differentiated cells, it remains to be elucidated whether any specific subpopulations are sensitive to reprogramming in heterogeneous tumor tissues. Here we examined the susceptibility of pancreatic cancer stem cells (CSC) and non-CSC to reprogramming. To characterize CSC populations, we focused on c-Met signaling, which has been identified as a marker of CSC in mouse experiments in vivo. Cells that expressed high levels of c-Met showed higher CSC properties, such as tumor-initiating capacity, and resistance to gemcitabine. Real-time reverse transcription-polymerase chain reaction in cells expressing high levels of c-Met revealed endogenous expression of reprogramming factors, such as OCT3/4, SOX2, KLF4 and cMYC. Introduction of these four factors resulted in higher alkaline phosphatase staining in cells with high c-Met expression than in controls. Therefore, the study results demonstrate that cellular reprogramming may be useful for extensive epigenetic modification of malignant features of pancreatic CSC.

AB - Previous reports have indicated that reprogramming technologies may be useful for altering the malignant phenotype of cancer cells. Although somatic stem cells in normal tissues are more sensitive to reprogramming induction than differentiated cells, it remains to be elucidated whether any specific subpopulations are sensitive to reprogramming in heterogeneous tumor tissues. Here we examined the susceptibility of pancreatic cancer stem cells (CSC) and non-CSC to reprogramming. To characterize CSC populations, we focused on c-Met signaling, which has been identified as a marker of CSC in mouse experiments in vivo. Cells that expressed high levels of c-Met showed higher CSC properties, such as tumor-initiating capacity, and resistance to gemcitabine. Real-time reverse transcription-polymerase chain reaction in cells expressing high levels of c-Met revealed endogenous expression of reprogramming factors, such as OCT3/4, SOX2, KLF4 and cMYC. Introduction of these four factors resulted in higher alkaline phosphatase staining in cells with high c-Met expression than in controls. Therefore, the study results demonstrate that cellular reprogramming may be useful for extensive epigenetic modification of malignant features of pancreatic CSC.

UR - http://www.scopus.com/inward/record.url?scp=84942191207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942191207&partnerID=8YFLogxK

U2 - 10.1111/cas.12734

DO - 10.1111/cas.12734

M3 - Article

C2 - 26298849

AN - SCOPUS:84942191207

VL - 106

SP - 1182

EP - 1187

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 9

ER -